U.S. Household Products Stock News

NasdaqGS:SLDE
NasdaqGS:SLDEInsurance

Assessing Slide Insurance Holdings (SLDE) Valuation After Recent Share Price Momentum

With no specific headline event driving Slide Insurance Holdings (SLDE) today, recent trading and fundamentals provide more of the story. The stock last closed at $19.00, with mixed short term returns. See our latest analysis for Slide Insurance Holdings. The recent 7 day share price return of 12.6% and 30 day share price return of 18.9%, on top of a positive 90 day share price move, point to building momentum despite a softer 1 day pullback. If this kind of move has you looking beyond a...
NYSE:PSA
NYSE:PSASpecialized REITs

Is It Time To Reassess Public Storage (PSA) After Recent Share Price Strength

If you are wondering whether Public Storage is fairly priced at around US$307 a share, you are not alone; many investors are trying to work out what they are actually paying for here. The stock has recently posted returns of 0.7% over 7 days, 12.1% over 30 days, 18.8% year to date, 5.4% over 1 year, 13.9% over 3 years, and 61.9% over 5 years, which is prompting fresh questions about both growth potential and risk. Recent coverage has focused on Public Storage as a major US self storage REIT,...
NYSE:POR
NYSE:PORElectric Utilities

Assessing Portland General Electric (POR) Valuation After Equity Raises And PacifiCorp Acquisition News

Portland General Electric (POR) has quickly moved into the spotlight after completing follow-on equity offerings of about US$480 million and agreeing to buy PacifiCorp utility assets in Washington state, which are linked to growing generative AI power demand. See our latest analysis for Portland General Electric. Alongside the follow on equity offerings and PacifiCorp acquisition plans, Portland General Electric’s share price has been firm, with an 8.1% 1 month share price return and 11.4%...
NasdaqGS:COGT
NasdaqGS:COGTBiotechs

A Look At Cogent Biosciences (COGT) Valuation After A Strong One Year Shareholder Return

Stock performance snapshot and business context Cogent Biosciences (COGT) has recently seen mixed share performance, with a 1.5% decline over the past day, a 4.0% gain over the past week, a 1.3% rise over the past month, and a 3.4% decline over the past 3 months. Year to date, the stock is up 11.8%, and the reported 1 year total return is 415.9%, with a 3 year total return of 187.9% and a 5 year total return of 389.9%. The company is a clinical stage biotechnology business focused on...
NasdaqGS:SLM
NasdaqGS:SLMConsumer Finance

SLM (SLM) Is Down 17.1% After Inflation Data Spurs Cost Jitters Has The Bull Case Changed?

SLM Corporation recently saw its shares react sharply after a stronger-than-expected US Producer Price Index report highlighted rising wholesale inflation pressures, intensifying investor focus on inflation risks for financial firms. This move comes after an earlier sharp drop linked to concerns over higher expenses and earnings revisions, underscoring how sensitive SLM’s valuation is to shifts in cost expectations and macroeconomic data. We’ll now examine how heightened inflation worries...
NYSE:VNT
NYSE:VNTElectronic

How Investors Are Reacting To Vontier (VNT) Pairing Driivz EV Deal With New Innovation Chief

Earlier this month, Vontier Corporation’s Driivz subsidiary announced a partnership with XLR8 America to manage and optimize over 5,000 EV charging sites on its hardware-agnostic software platform, while Vontier also declared a regular quarterly cash dividend of US$0.025 per share payable on March 26, 2026. Vontier further reinforced its focus on innovation and digital growth by appointing Rasha Hasaneen as Chief Innovation and Growth Officer to lead enterprise innovation, AI strategy and...
NYSE:WHR
NYSE:WHRConsumer Durables

Whirlpool (WHR) Is Down 19.0% After Dilutive Recapitalization and Appaloosa Rebuke - Has The Bull Case Changed?

In late February 2026, Whirlpool completed roughly US$475 million of follow-on common equity issuance and about US$1.58 billion of preferred and depositary share offerings to repay debt and fund corporate initiatives, triggering sharp criticism from major shareholder Appaloosa over dilution and capital allocation. Appaloosa’s public rebuke of Whirlpool’s board and management, including calls to invite potential partners or buyers, injects governance and control questions directly into the...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

A Look At Shoals Technologies Group (SHLS) Valuation After Record Results And New AI Data Center Partnership

Shoals Technologies Group (SHLS) is back in focus after reporting record quarterly revenue and backlog, issuing 2026 guidance, and announcing an ON.energy partnership targeting power systems for AI data centers and battery storage. See our latest analysis for Shoals Technologies Group. Despite record revenue and a large backlog, Shoals’ recent earnings miss and new guidance coincided with a sharp reset in sentiment. A 7 day share price return of a 44.1% decline and a 1 year total shareholder...
NasdaqGM:USAR
NasdaqGM:USARMetals and Mining

Is It Time To Revisit USA Rare Earth (USAR) After Its Recent Share Price Swings

If you are trying to figure out whether USA Rare Earth is attractively priced or already baking in a lot of optimism, you are in the right place. The stock last closed at US$18.90, with returns of 9.7% over the past week, a 14.4% decline over the last 30 days, and gains of 33.6% year to date and 69.8% over the past year. That performance will catch the eye of anyone tracking shifts in risk and reward. Recent attention on USA Rare Earth has focused on its role in rare earth supply chains and...
NasdaqCM:CELH
NasdaqCM:CELHBeverage

Celsius Revenue Record Expands Beverage Platform And Raises Valuation Questions

Celsius Holdings (NasdaqCM:CELH) reported record full year revenue in 2025. Results were driven by the acquisitions and integration of Alani Nu and Rockstar Energy. The company further integrated into the PepsiCo system and expanded internationally. Celsius launched a new brand studio and a Fizz Free product line during 2025. Celsius Holdings operates in the energy drink category, a segment that continues to attract strong consumer attention as shoppers look for functional beverages and...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

Does First Bancorp (FBNC)’s Liquidity Playbook Clarify or Complicate Its Profitability Story?

In its recently filed 2025 10-K, First Bancorp outlined past actions to strengthen liquidity and capital, including reinvesting in higher-yielding securities and maintaining a diversified deposit base, while reporting a 14.4% increase in shareholders’ equity and a CET1 ratio of 14.10%. The filing also underscored a business mix shift toward more variable-rate loans and relatively weak revenue growth and net interest margin versus peers, sharpening investor focus on how the bank manages...
NYSE:UBER
NYSE:UBERTransportation

Is Uber Technologies (UBER) Still Attractive After Recent Share Price Weakness?

If you are wondering whether Uber Technologies is priced attractively right now, you are not alone. A closer look at its current valuation can help you decide how it fits into your portfolio. Uber shares last closed at US$75.42, with returns of 2.1% over the past 7 days, a 5.5% decline over 30 days, a 9.0% decline year to date, a 0.8% decline over 1 year, a 118.2% gain over 3 years and a 35.8% gain over 5 years. Recent headlines around Uber have continued to focus on its role as a major...
NasdaqCM:SBET
NasdaqCM:SBETHospitality

Sharplink Hires Digital Asset Journalist To Refine Ethereum Investment Narrative

Sharplink (NasdaqCM:SBET) has appointed digital assets specialist Steven Ehrlich as Head of Research and Communications. Ehrlich brings experience from prior roles at Forbes and Unchained, where he focused on digital asset journalism and research. The appointment marks a change in Sharplink’s leadership team aimed at strengthening its research and communication function. For investors, this move sits at the intersection of media, data, and digital assets, an area that continues to attract...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Clover Health (CLOV) Q4 Loss Worsening Challenges Bullish Path To Profitability Narratives

Clover Health Investments FY 2025 Earnings Snapshot Clover Health Investments (CLOV) has wrapped up FY 2025 with Q4 revenue of US$487.7 million and a basic EPS loss of US$0.10, alongside a trailing 12 month revenue figure of about US$1.9 billion and a basic EPS loss of US$0.17 that keeps the company in loss making territory. Over the past few quarters, the company has seen quarterly revenue move from US$462.3 million in Q1 2025 to US$496.7 million in Q3 2025 before ending the year at US$487.7...
NasdaqGS:ADSK
NasdaqGS:ADSKSoftware

Autodesk (ADSK) Margin Compression Challenges Bullish Earnings Growth Narrative After FY 2026 Results

Autodesk (ADSK) has wrapped up FY 2026 with Q4 revenue of US$1.96b and basic EPS of US$1.49, alongside trailing twelve month revenue of US$7.21b and EPS of US$5.28, setting a clear reference point for how the business is currently performing. Over recent periods, the company has seen revenue move from US$6.13b on a trailing basis in FY 2025 to US$7.21b in FY 2026, while trailing EPS shifted from US$5.17 to US$5.28. This gives investors a clearer view of how top line scale and per share...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Is Grab Holdings (GRAB) Pricing Looked At Differently After Recent Share Price Weakness

If you are wondering whether Grab Holdings is attractively priced at its current level, this article will walk through what the latest data suggests about its valuation. The stock most recently closed at US$4.22, with returns of 3.7% decline over 7 days, 6.8% decline over 30 days, 16.9% decline year to date, 13.0% decline over 1 year, 28.7% over 3 years and 63.4% decline over 5 years, which may prompt questions about how the market is reassessing its potential and risks. Recent coverage...
NYSE:DGX
NYSE:DGXHealthcare

A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Momentum

Why Quest Diagnostics is on investors’ radar today Quest Diagnostics (DGX) is drawing attention after recent share price moves, with the stock last closing at $211.91 and showing double digit total returns over the past year and past 3 months. See our latest analysis for Quest Diagnostics. The recent share price strength, including a 15.96% 1 month share price return and 21.93% year to date share price return, sits alongside a 1 year total shareholder return of 24.84%. This points to momentum...
NYSE:STT
NYSE:STTCapital Markets

Is State Street’s New MyIncome ETFs and Dividends Altering The Investment Case For State Street (STT)?

In February 2026, State Street Investment Management launched five actively managed State Street MyIncome target-maturity high-yield corporate bond ETFs maturing between 2027 and 2031, while State Street Corporation declared cash dividends on its common and multiple preferred stock series payable in March and April 2026. This combination of new income-focused ETFs and ongoing preferred and common dividends highlights State Street’s effort to broaden fee-based products while continuing cash...
NasdaqGS:CACC
NasdaqGS:CACCConsumer Finance

Assessing Credit Acceptance (CACC) Valuation After Recent Share Price Strength

With no single headline event driving today’s move, Credit Acceptance (CACC) is drawing attention as investors weigh its recent share performance and current valuation signals in relation to the company’s latest reported fundamentals. See our latest analysis for Credit Acceptance. At a share price of $473.18, Credit Acceptance has seen a 9.17% 1 month share price return and a 4.24% year to date share price return, while its 1 year total shareholder return decline of 3.90% and 5 year total...
NYSE:EMN
NYSE:EMNChemicals

Eastman Chemical’s New Bond Issue And What It Means For Investors

Eastman Chemical (NYSE:EMN) has completed a major fixed-income offering of unsecured notes with a fixed coupon and long maturity. The new issuance adjusts the company’s capital structure and adds a long term funding source to its balance sheet. This move has implications for liquidity, interest costs, and how Eastman approaches future borrowing and investment decisions. For investors watching NYSE:EMN, this bond deal comes after a mixed share price track record, with the stock at $75.51 and...
NYSE:ELF
NYSE:ELFPersonal Products

How TikTok Launches, Rhode Upgrade, and Governance Scrutiny Will Impact e.l.f. Beauty (ELF) Investors

In recent months, e.l.f. Beauty has accelerated customer‑driven product launches via TikTok Live, expanded its hit Glow Reviver lip balm line with a limited‑edition dill pickle flavor, raised its fiscal 2026 revenue guidance on stronger‑than‑expected Rhode performance, and drawn both a fiduciary‑duty investigation and shifting short‑interest levels. Taken together, these developments highlight how e.l.f. is leaning on rapid innovation, social‑media engagement, and the Rhode acquisition...
NasdaqGS:PLMR
NasdaqGS:PLMRInsurance

A Look At Palomar Holdings (PLMR) Valuation After New US$125 Million Shelf Registration Filing

Palomar Holdings (PLMR) recently filed a shelf registration for up to US$125.05 million in common stock, covering 1,035,613 shares. This filing gives the insurer flexibility to issue equity for future ESOP related initiatives. See our latest analysis for Palomar Holdings. Against this backdrop, Palomar’s 1 day share price return of 1.53% and recent 30 day gain of 3.35% contrast with a softer year to date share price return of 6.15% and a 1 year total shareholder return of 3.85%. At the same...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte (INCY) Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential

Incyte (INCY) is back in focus after Eli Lilly and Incyte received a positive opinion from the European Medicines Agency for extending Olumiant to adolescents with severe alopecia areata, marking a new regulatory milestone for the partnership. See our latest analysis for Incyte. While the latest EMA opinion has put Incyte back in the headlines, the share price has been relatively steady in the short term, with recent 1 day and 30 day share price returns close to flat. However, the 1 year...
NYSE:A
NYSE:ALife Sciences

Agilent’s New FDA Approval And What It Could Mean For Investors

Agilent Technologies (NYSE:A) received FDA approval for its PD-L1 IHC 22C3 pharmDx as the only authorized companion diagnostic for certain ovarian and related cancers treated with KEYTRUDA. The approval covers use of the assay to help identify patients who may be eligible for KEYTRUDA based on PD-L1 expression. The decision expands the clinical indications for PD-L1 IHC 22C3 pharmDx within Agilent's broader oncology diagnostics portfolio. For investors, this news sits at the intersection of...